Author:
Liu Fengying,He Huanhuan,Yang Weijie,Wang Daohui,Sui Xin,Sun Yangyang,Wang Shuai,Yang Yi,Xiao Zhenyu,Yang Jun,Wang Yongan,Luo Yuan
Abstract
Abstract
Background
Acute hypobaric hypoxia-induced brain injury has been a challenge in the health management of mountaineers; therefore, new neuroprotective agents are urgently required. Meldonium, a well-known cardioprotective drug, has been reported to have neuroprotective effects. However, the relevant mechanisms have not been elucidated. We hypothesized that meldonium may play a potentially novel role in hypobaric hypoxia cerebral injury.
Methods
We initially evaluated the neuroprotection efficacy of meldonium against acute hypoxia in mice and primary hippocampal neurons. The potential molecular targets of meldonium were screened using drug-target binding Huprot™ microarray chip and mass spectrometry analyses after which they were validated with surface plasmon resonance (SPR), molecular docking, and pull-down assay. The functional effects of such binding were explored through gene knockdown and overexpression.
Results
The study clearly shows that pretreatment with meldonium rapidly attenuates neuronal pathological damage, cerebral blood flow changes, and mitochondrial damage and its cascade response to oxidative stress injury, thereby improving survival rates in mice brain and primary hippocampal neurons, revealing the remarkable pharmacological efficacy of meldonium in acute high-altitude brain injury. On the one hand, we confirmed that meldonium directly interacts with phosphoglycerate kinase 1 (PGK1) to promote its activity, which improved glycolysis and pyruvate metabolism to promote ATP production. On the other hand, meldonium also ameliorates mitochondrial damage by PGK1 translocating to mitochondria under acute hypoxia to regulate the activity of TNF receptor-associated protein 1 (TRAP1) molecular chaperones.
Conclusion
These results further explain the mechanism of meldonium as an energy optimizer and provide a strategy for preventing acute hypobaric hypoxia brain injury at high altitudes.
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Davis C, Hackett P. Advances in the prevention and treatment of high altitude illness. Emerg Med Clin North Am. 2017;35:241–60.
2. Storz JF, Cheviron ZA. Physiological genomics of adaptation to high-altitude Hypoxia. Annu Rev Anim Biosci. 2021;9:149–71.
3. Wang H, Zhu X, Xiang H, Liao Z, Gao M, Luo Y, et al. Effects of altitude changes on mild-to-moderate closed-head injury in rats following acute high-altitude exposure. Exp Ther Med. 2019;17:847–56.
4. Luks AM, Hackett PH. Medical conditions and high-Altitude Travel. N Engl J Med. 2022;386:364–73.
5. Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003;361:1967–74.